Literature DB >> 24918800

Health care provider management of patients with type 2 diabetes mellitus: analysis of trends in attitudes and practices.

Chad Williamson1, Terry Ann Glauser, B Stephen Burton, Doron Schneider, Anne Marie Dubois, Daxa Patel.   

Abstract

OBJECTIVE: To identify attitudes and practices of endocrinologists (ENDOs), family practitioners (FPs), internists (IMs), primary care nurse practitioners (NPs), physician assistants (PAs), certified diabetes educators (CDEs), retail pharmacists (R-PHs), and hospital pharmacists (H-PHs) with respect to type 2 diabetes mellitus (T2DM) management; to compare current study data with results from a similar 2011 study.
METHODS: A nominal group technique focus group identified barriers to optimal management of patients with T2DM. Five case-vignette surveys were created, 1 for each group of health care professionals (HCPs): ENDOs; FPs and IMs; NPs and PAs; CDEs; and R-PHs and H-PHs. Surveys were tailored to each group. Versions were as similar as possible to each other and to the 2011 surveys to facilitate comparisons. Questions assessed guideline familiarity; knowledge of insulin formulations, glucagon-like peptide-1 (GLP-1) receptor agonists, dipeptidyl peptidase-4 (DPP-4) inhibitors; patterns of referral to ENDOs and CDEs; as well as cultural barriers and communication barriers. Surveys were distributed by e-mail/fax to a nationally representative, random sample of US HCPs during January and February 2013. RESULTS AND
CONCLUSIONS: Notable shifts from 2011 included NPs' increased familiarity with American Diabetes Association (ADA) guidelines; FPs, IMs, NPs, and PAs continued comfort with prescribing long-acting basal insulin but less with basal-bolus, Neutral Protamine Hagedorn insulin alone, or human premixed insulin; increased pharmacists' comfort in discussing long-acting basal insulin; increased likelihood that FPs will refer patients with recurrent hypoglycemia unable to achieve target glycated hemoglobin level to an ENDO; and continued incorporation of insulin and incretins into treatment regimens. The trends suggest gaps in perception, knowledge, and management practices to be addressed by education. Most HCPs lack confidence in using insulin regimens more complex than long-acting insulin alone. All providers need education on T2DM management guidelines, differences between GLP-1 agonists and DPP-4 inhibitors, and how to intensify therapy for patients not reaching goal blood glycemic level with use of multiple agents. Pharmacists might benefit from education on glycemic treatment goals.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24918800     DOI: 10.3810/pgm.2014.05.2764

Source DB:  PubMed          Journal:  Postgrad Med        ISSN: 0032-5481            Impact factor:   3.840


  7 in total

1.  Physicians' and Pharmacists' Clinical Considerations for Elderly Patients with Type 2 Diabetes Mellitus: The IMPLICA2 Study.

Authors:  Josep Franch-Nadal; Fermín García-Gollarte; Alfonso Pérez Del Molino; María L Orera-Peña; Marta Rodríguez de Miguel; Malena Melogno-Klinkas; Héctor D de Paz; Susana Aceituno; Patricia Rodríguez-Fortúnez
Journal:  Clin Drug Investig       Date:  2019-01       Impact factor: 2.859

2.  Effect of Ranolazine Monotherapy on Glycemic Control in Subjects With Type 2 Diabetes.

Authors:  Robert H Eckel; Robert R Henry; Patrick Yue; Arvinder Dhalla; Pamela Wong; Philip Jochelson; Luiz Belardinelli; Jay S Skyler
Journal:  Diabetes Care       Date:  2015-06-06       Impact factor: 19.112

3.  The SWEET SPOTS study: a real-world interpretation of the 2012 American Diabetes Association Position Statement regarding individualized A1C targets.

Authors:  Nella Bieszk; Michael Grabner; Wenhui Wei; Nicole G Bonine; Judith J Stephenson
Journal:  Risk Manag Healthc Policy       Date:  2016-11-08

Review 4.  Gaps and barriers in the control of blood glucose in people with type 2 diabetes.

Authors:  Lawrence Blonde; Pablo Aschner; Clifford Bailey; Linong Ji; Lawrence A Leiter; Stephan Matthaei
Journal:  Diab Vasc Dis Res       Date:  2017-02-01       Impact factor: 3.291

5.  Room for Improvement: The HIV-Diabetes Care Continuum Over 15 Years in the Women's Interagency HIV Study.

Authors:  Jonathan Colasanti; Karla I Galaviz; C Christina Mehta; Kartika Palar; Michael F Schneider; Phyllis Tien; Adaora A Adimora; Maria Alcaide; Mardge H Cohen; Deborah Gustafson; Roksana Karim; Daniel Merenstein; Anjali Sharma; Gina Wingood; Vincent C Marconi; Ighovwerha Ofotokun; Mohammed K Ali
Journal:  Open Forum Infect Dis       Date:  2018-05-22       Impact factor: 3.835

6.  BeAM value: an indicator of the need to initiate and intensify prandial therapy in patients with type 2 diabetes mellitus receiving basal insulin.

Authors:  Ariel Zisman; Francienid Morales; John Stewart; Andreas Stuhr; Aleksandra Vlajnic; Rong Zhou
Journal:  BMJ Open Diabetes Res Care       Date:  2016-04-13

Review 7.  Ranolazine: A Contemporary Review.

Authors:  Erin Rayner-Hartley; Tara Sedlak
Journal:  J Am Heart Assoc       Date:  2016-03-15       Impact factor: 5.501

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.